Cancer genome analysis through next-generation sequencing

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 1, 2011, Pages 1-6

  Aburatani, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer genome; Molecular target; Next generation sequencing

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER CELL; CANCER GENETICS; CHROMOSOME REARRANGEMENT; COPY NUMBER VARIATION; DNA SEQUENCE; EPIGENETICS; GENE TRANSLOCATION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; INDEL MUTATION; MUTATION; REVIEW;

EID: 79957568237     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Eid J, Fehr A, Gray J, et al: Real-time DNA sequencing from single polymerase molecules. Science 323(5910): 133-138, 2009.
2. Deamer D: Nanopore analysis of nucleic acids bound to exonucleases and polymerases. Annu Rev Biophys 39: 79-90, 2010.
3. http://cancergenome.nih.gov/
4. The Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068, 2008.
5. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1): 98-110, 2010.
6. Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218): 66-72, 2008.
7. Pleasance ED, Cheetham RK, Stephens PJ, et al: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278): 191-196, 2010.
8. Pleasance ED, Stephens PJ, O'Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278): 184-190, 2010.
9. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291): 999-1005, 2010.
10. Lee W, Jiang Z, Liu J, et al: The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465(7297): 473-477, 2010.
11. Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319): 1109-1113, 2010.
12. http://www.icgc.org/
13. International Cancer Genome Consortium: International network of cancer genome projects. Nature 464(7291): 993-998, 2010.
14. Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science 318(5853): 1108-1113, 2007. (Pubitemid 350134889)
15. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897): 1801-1806, 2008.
16. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897): 1807-1812: 2008.
17. Teer JK, Bonnycastle LL, Chines PS, et al: Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. Genome Res 20 (10): 1420-1431, 2010.
18. Gnirke A, Melnikov A, Maguire J, et al: Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27(2): 182-189, 2009.
19. Tewhey R, Warner JB, Nakano M, et al: Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol 27(11): 1025-1031, 2009.
20. Dalgliesh GL. Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279): 360-363, 2010.
21. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16(7): 793-798, 2010.
22. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18): 1693-1703, 2010.
23. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18): 1734-1739, 2010.
24. Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16): 1532-1543, 2010.
25. Lister R, Pelizzola M, Dowen RH, et al: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271): 315-322, 2009.
26. Bock C, Tomazou EM, Brinkman AB, et al: Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 28(10): 1106-1114, 2010.
27. Markowitz SD and Bertagnolli MM: Molecular origins of cancer Molecular basis of colorectal cancer. N Engl J Med 361(25): 2449-2460, 2009.
28. Lièvre A, Blons H and Laurent-Puig P: Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29(21): 3033-3043, 2010.
29. Barault L, Veyrie N, Jooste V, et al: Mutations in the RAS-MAPK, PI (3) K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122(10): 2255-2259, 2008. (Pubitemid 351542328)
30. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8): 3992-3995, 2006.
31. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35): 5705-5712, 2008.
32. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5): 1851-1857, 2009.
33. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19): 1308-1324, 2009.
34. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16): 1812-1820, 2010.
35. Urbanova M, Plzak J, Strnad H, et al: Circulating nucleic acids as a new diagnostic tool. Cell Mol Biol Lett 15(2): 242-259, 2010.
36. Diehl F, Schmidt K, Choti MA, et al: Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9): 985-990, 2008.
37. Nagrath S, Sequist LV, Maheswaran S, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173): 1235-1239, 2007.
38. Leary RJ, Kinde I, Diehl F, et al: Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2(20): 20ra14, 2010.